169 related articles for article (PubMed ID: 32206949)
21. ASO Author Reflections: Esophageal Squamous Cell Carcinoma-Still a Conundrum.
Squires MH; Salo JC
Ann Surg Oncol; 2022 Feb; 29(2):1334-1335. PubMed ID: 34674090
[No Abstract] [Full Text] [Related]
22. ASO Author Reflections: Appropriate Candidates for Salvage Esophagectomy of Initially Unresectable Locally Advanced T4 Esophageal Squamous Cell Carcinoma.
Booka E; Haneda R; Ishii K; Tsubosa Y
Ann Surg Oncol; 2020 Sep; 27(9):3171-3172. PubMed ID: 32270418
[No Abstract] [Full Text] [Related]
23. ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma.
Shimizu H; Katsurahara K; Inoue H; Shiozaki A; Otsuji E
Ann Surg Oncol; 2022 Dec; 29(13):8688-8689. PubMed ID: 35986132
[No Abstract] [Full Text] [Related]
24. ASO Author Reflections: Treatment Strategies for Locally Advanced Borderline Resectable Esophageal Squamous Cell Carcinoma.
Hong Y
Ann Surg Oncol; 2024 Feb; 31(2):896. PubMed ID: 37962739
[No Abstract] [Full Text] [Related]
25. ASO Author Reflections: Can Circulating Tumor DNA Guide Individualized Treatment for Patients with Esophageal Squamous Cell Carcinoma?
Morimoto Y; Matsuda S; Kawakubo H; Nakamura K; Kobayashi R; Hisaoka K; Okui J; Takeuchi M; Aimono E; Fukuda K; Nakamura R; Saya H; Nishihara H; Kitagawa Y
Ann Surg Oncol; 2023 Jun; 30(6):3757-3758. PubMed ID: 36807023
[No Abstract] [Full Text] [Related]
26. ASO Author Reflections: Safety of Elective Esophagectomy Performed on Weekend for Patients with Esophageal Carcinoma.
Yang TY; Chao YK
Ann Surg Oncol; 2023 Jun; 30(6):3799. PubMed ID: 36905439
[No Abstract] [Full Text] [Related]
27. ASO Author Reflections: Optimizing Proximal Esophageal Squamous Cell Carcinoma Treatment.
Patel DC; Berry MF
Ann Surg Oncol; 2023 Feb; 30(2):828-829. PubMed ID: 36258059
[No Abstract] [Full Text] [Related]
28. ASO Author Reflections: Association Between Preoperative Coagulation Status and Prognosis in Patients Undergoing Subtotal Esophagectomy for Esophageal Squamous Cell Carcinoma After Neoadjuvant Treatment.
Sugiyama F; Kanda M; Kodera Y
Ann Surg Oncol; 2024 May; 31(5):3473-3474. PubMed ID: 38261127
[No Abstract] [Full Text] [Related]
29. ASO Author Reflections: Prognostic Stratification and the Value of Adjuvant Therapy in Thoracic Esophageal Squamous Cell Carcinoma Patients After Esophagectomy.
Deng W; Chen J; Xiao Z
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):802-803. PubMed ID: 31654164
[No Abstract] [Full Text] [Related]
30. ASO Author Reflections: Prediction of the Therapeutic Efficacy in Patients with Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Okamura A; Matsuda S; Kawakubo H; Mine S; Takeuchi H; Kitagawa Y; Watanabe M
Ann Surg Oncol; 2020 Dec; 27(Suppl 3):795-796. PubMed ID: 32591950
[No Abstract] [Full Text] [Related]
31. ASO Author Reflections: Prognostic Role of a Coagulation Index for Patients with Esophageal Squamous Cell Cancer.
Wang Q; Cao B; Mi K
Ann Surg Oncol; 2021 Dec; 28(13):8462-8463. PubMed ID: 34106387
[No Abstract] [Full Text] [Related]
32. ASO Author Reflections: The Lymph Node Ratio is an Independent Prognostic Factor in Esophageal Squamous Cell Carcinoma After Minimally Invasive Esophagectomy.
Kitamura Y; Oshikiri T
Ann Surg Oncol; 2021 Aug; 28(8):4529. PubMed ID: 33399999
[No Abstract] [Full Text] [Related]
33. ASO Author Reflections: Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma.
Chan WL
Ann Surg Oncol; 2023 Feb; 30(2):871-872. PubMed ID: 36380255
[No Abstract] [Full Text] [Related]
34. ASO Author Reflections: A Novel, Sensitive, and Effective Index in Predicting Therapeutic Response of Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma.
Feng J; Wang L; Yang X; Chen Q; Cheng X
Ann Surg Oncol; 2024 Jan; 31(1):241-242. PubMed ID: 37838649
[No Abstract] [Full Text] [Related]
35. ASO Author Reflections: Prognostic Significance of Kallikrein-Related Peptidase 13 Induction After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma.
Shimomura A; Yamada K; Kawamura YI
Ann Surg Oncol; 2024 Jan; 31(1):243-244. PubMed ID: 37851200
[No Abstract] [Full Text] [Related]
36. ASO Author Reflections: Comparison of Aggressive Planned Salvage Surgery versus Neoadjuvant Chemoradiotherapy Plus Surgery for Borderline Resectable T4 Squamous Cell Carcinoma.
Shiraishi O
Ann Surg Oncol; 2021 Oct; 28(11):6376-6377. PubMed ID: 33830358
[No Abstract] [Full Text] [Related]
37. ASO Author Reflections: Biomarkers for Neoadjuvant Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma.
Okumura H; Noda M; Natsugoe S
Ann Surg Oncol; 2018 Dec; 25(Suppl 3):715-716. PubMed ID: 30288651
[No Abstract] [Full Text] [Related]
38. Second primary head and neck cancer risk among patients with esophageal squamous cell carcinoma after curative esophagectomy.
Hung TC; Liu C; Tsai PC; Hsieh CC; Hsu PK; Huang CS; Hsu HS
J Gastrointest Surg; 2024 Feb; 28(2):167-169. PubMed ID: 38445939
[No Abstract] [Full Text] [Related]
39. ASO Author Reflections: Timing of Surgery and Chemoradiation for Esophageal Squamous Cell Carcinoma.
Wong LY; Berry MF
Ann Surg Oncol; 2023 Apr; 30(4):2224-2225. PubMed ID: 36607525
[No Abstract] [Full Text] [Related]
40. ASO Author Reflections: Intramural Metastasis as Dismal Prognostic Factor in Esophageal Squamous Cell Carcinoma.
Ushimaru Y; Makino T; Doki Y
Ann Surg Oncol; 2023 Aug; 30(8):5203-5204. PubMed ID: 37285094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
